a month ago
BCRX
AnalystsJonathan WollebenJonathan Wolleben's Stock Forecasts
AnalystsJonathan Wolleben
Analyst Ranking
Top 3%
#105 out of 5134 analysts
Average Return
+20.41%
Win Rate
55%130 out of 236
Risk vs Reward
Poor
Good
Jonathan Wolleben's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Mbx Biosciences IncMBX | +409.89% | $6.27 | $31.97 | 2025-04-10 - 2025-12-05 | Buy |
Madrigal Pharmaceuticals IncMDGL | +365.01% | $64.44 | $299.65 | 2022-05-10 - 2023-05-09 | Buy |
Dbv Technologies SaDBVT | +302.90% | $3.45 | $13.90 | 2024-12-10 - 2025-12-05 | Buy |
Dbv Technologies SaDBVT | +223.26% | $4.30 | $13.90 | 2025-03-04 - 2025-12-05 | Buy |
Sagimet Biosciences IncSGMT | +214.13% | $2.76 | $8.67 | 2024-08-15 - 2025-08-14 | Buy |
Jonathan Wolleben Analyst Color
Get additional color on Jonathan Wolleben's coverage of popular stocks
2 months ago
BCRX
a year ago
SPOT
Jonathan Wolleben's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Sagimet Biosciences IncSGMT | 9 | Buy | $35.00 | +447.73% | Maintains | 23 days ago |
Savara IncSVRA | 10 | Buy | $10.00 | +53.85% | Maintains | 25 days ago |
Spruce Biosciences IncSPRB | 8 | Buy | $259.00 | +223.79% | Maintains | a month ago |
Kalvista Pharmaceuticals IncKALV | 6 | Buy | $28.00 | +70.42% | Maintains | a month ago |
Protagonist Therapeutics IncPTGX | 13 | Buy | $102.00 | +13.78% | Maintains | a month ago |
Crinetics Pharmaceuticals IncCRNX | 17 | Buy | $108.00 | +131.41% | Maintains | a month ago |
Altimmune IncALT | 13 | Buy | $14.00 | +167.18% | Maintains | a month ago |
Biocryst Pharmaceuticals IncBCRX | 10 | Buy | $25.00 | +229.38% | Maintains | a month ago |
Madrigal Pharmaceuticals IncMDGL | 12 | Buy | $527.00 | -8.71% | Maintains | a month ago |
Mirum Pharmaceuticals IncMIRM | 12 | Buy | $95.00 | +38.73% | Maintains | a month ago |
Kalaris Therapeutics IncKLRS | 1 | Buy | $20.00 | +239.85% | Initiates Coverage On | a month ago |
Ocular Therapeutix IncOCUL | 16 | Buy | $29.00 | +130.52% | Maintains | 2 months ago |
Rhythm Pharmaceuticals IncRYTM | 5 | Buy | $142.00 | +35.76% | Maintains | 2 months ago |
Larimar Therapeutics IncLRMR | 13 | Buy | $18.00 | +386.49% | Reiterates | 4 months ago |
Pharvaris NvPHVS | 12 | Buy | $52.00 | +96.82% | Maintains | 4 months ago |
Astria Therapeutics IncATXS | 3 | Buy | $26.00 | +101.08% | Maintains | 4 months ago |
Quince Therapeutics IncQNCX | 2 | Buy | $8.00 | +99.50% | Maintains | 4 months ago |
Structure Therapeutics IncGPCR | 10 | Buy | $87.00 | +151.74% | Maintains | 4 months ago |
Proqr Therapeutics NvPRQR | 6 | Buy | $8.00 | +282.78% | Reiterates | 5 months ago |
Dbv Technologies SaDBVT | 15 | Buy | $21.00 | +51.08% | Reiterates | 5 months ago |
Skye Bioscience IncSKYE | 3 | Buy | $15.00 | +1,150.00% | Reiterates | 5 months ago |
Aura Biosciences IncAURA | 9 | Buy | $19.00 | +195.49% | Reiterates | 6 months ago |
Clearside Biomedical IncCLSDQ | 11 | Buy | $75.00 | +18,192.68% | Reiterates | 7 months ago |
Mbx Biosciences IncMBX | 1 | Buy | $38.00 | +18.86% | Initiates Coverage On | 8 months ago |
Hilton Grand Vacations IncHGV | 1 | Buy | $50.00 | +18.04% | Maintains | a year ago |
Costar Group IncCSGP | 1 | Buy | $90.00 | +32.33% | Reiterates | a year ago |
Spotify Technology SaSPOT | 1 | Buy | $485.00 | N/A | Downgrades | a year ago |
Allakos IncALLK | 6 | Buy | $3.00 | N/A | Reiterates | a year ago |
Rallybio CorpRLYB | 11 | Buy | $8.00 | N/A | Reiterates | 2 years ago |
Warner Music Group CorpWMG | 1 | Buy | $24.00 | N/A | Maintains | 3 years ago |
Strongbridge Biopharma PLCSBBP | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.